West Pharmaceutical Appoints New CEO
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 02 2026
0mins
Source: NASDAQ.COM
- Executive Transition: West Pharmaceutical announced Michel Lagarde will succeed Eric Green as CEO effective August 31, 2026, bringing extensive industry experience from his previous role as COO at Thermo Fisher Scientific, which is expected to drive company growth.
- Board Changes: Concurrently, Robert F. Friel has been elected as Board Chair, effective the same date, aiming to strengthen corporate governance and ensure a smooth leadership transition during this critical period.
- Stock Price Movement: West Pharmaceutical closed at $316.3 on Monday, down 2.02%, but shares rose 0.40% in after-hours trading to $317.56, indicating market optimism regarding the new CEO's appointment.
- Industry Impact: Lagarde's appointment may influence the company's strategic direction, particularly in the injectable solutions and services sector, leveraging his extensive experience in healthcare services to drive growth in a competitive market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy WST?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on WST
Wall Street analysts forecast WST stock price to rise
12 Analyst Rating
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 323.590
Low
285.00
Averages
348.70
High
375.00
Current: 323.590
Low
285.00
Averages
348.70
High
375.00
About WST
West Pharmaceutical Services Inc. is a global manufacturer in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. Its segments include Proprietary Products and West Vantage. Its Proprietary Products segment offers proprietary packaging, containment solutions and drug delivery systems, along with analytical lab services and other integrated services and solutions, primarily for biologic, generic and pharmaceutical drug customers. Its West Vantage segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, as well as combination product assembly and packaging, primarily for pharmaceutical, diagnostic, and medical device customers. It also maintains collaborations to share technologies and market products with affiliates in Japan and Mexico. Its customers include generic, pharmaceutical, diagnostic, and medical device companies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cardinal Health Continues Growth with Stock Price Surge
- Outstanding Stock Performance: Cardinal Health achieved a remarkable 74% stock price increase in 2025, followed by a 7.9% rise year-to-date in 2026, reflecting sustained investor confidence in its growth strategy, significantly outperforming peers McKesson and Cencora.
- Enhanced Profitability: In its fiscal Q3 2026 earnings report, the company reported a 35% EPS growth and raised its earnings guidance again, underscoring management's confidence in sustained operational momentum despite macro uncertainties and pricing pressures.
- Strong Specialty Pharmaceutical Business: Cardinal Health's Pharmaceutical and Specialty Solutions segment saw an 11% revenue increase to $56.1 billion and an 18% profit rise in Q3, with expectations for specialty sales to exceed $50 billion in fiscal 2026, indicating robust growth potential in the market.
- Rapid Expansion of New Businesses: The company's
See More
US Stocks Close: Nasdaq Hits 5-Week Low Amid Market Rotations
- Market Volatility: The S&P 500 index fell by 0.26% and the Nasdaq 100 dropped by 1.12% on Tuesday, indicating a shift to a downward trend after an early advance, reflecting investor concerns over tech stocks.
- Energy Price Impact: WTI crude oil prices plunged by 3% to a seven-week low, leading to widespread declines in energy producers' stocks, which exacerbated the overall market weakness and highlighted the direct impact of oil price fluctuations on related sectors.
- Real Estate Market Recovery: US existing home sales rose to 4.17 million in April, a five-month high, boosting the stocks of builders and suppliers, indicating that a recovery in the real estate market could provide positive signals for the economy.
- International Trade Data Improvement: China's May exports increased by 19.4% year-on-year, surpassing expectations, showcasing potential for global economic growth, which may positively influence the US market, despite ongoing uncertainties.
See More
US Stock Market Volatility Amid Falling WTI Crude Prices
- Mixed Market Performance: The S&P 500 index fell by 0.28%, while the Dow Jones Industrial Average rose by 0.19%, and the Nasdaq 100 index dropped by 0.80%, indicating a divergence in market sentiment, particularly with weakness in chipmakers and software stocks weighing on the broader market.
- Crude Oil Price Decline: WTI crude oil prices plunged over 3% to a one-week low, primarily due to the ceasefire agreement between Iran and Israel, leading to expectations of further declines in oil prices that could impact the profitability outlook for energy stocks.
- Positive Economic Data: The US trade deficit narrowed to $55.9 billion in April, better than the expected $56.1 billion, while existing home sales in May rose by 3.2% month-over-month to 4.17 million, indicating resilience in the housing market that may provide support for stocks.
- Company Movements: United Natural Foods saw its stock drop over 12% after reporting Q3 net sales below expectations, while Nuvalent's stock surged over 38% following GSK's agreement to acquire the company for $10.6 billion, reflecting varied market reactions to company fundamentals.
See More
Barclays Upgrades West Pharmaceutical to Overweight, Predicts Upside
- Rating Upgrade: Barclays upgraded West Pharmaceutical (WST) from Equal Weight to Overweight, with analysts citing strong fundamentals that could drive near-term upside, reflecting market confidence in the company's future performance.
- Fundamental Improvement: Analyst Luke Sergott noted that previous overestimations of potential headwinds from multi-dose vials and new oral GLP-1 drugs are not expected to pose significant threats in the coming years, suggesting a more favorable outlook.
- Leadership Advantage: The leadership of newly appointed CEO Michel Lagarde and CFO Bob McMahon, who joined last year, is highlighted as a key factor that could facilitate the company's growth and diversification over the next few years.
- Price Target Increase: Barclays raised its price target for WST from $310 to $400, reflecting analysts' optimistic expectations regarding the company's untapped balance sheet capacity and capital deployment flexibility.
See More
US Stocks Rebound as AI Trade Continues to Gain Momentum
- Market Rebound: The S&P 500 Index rose by 0.93%, the Dow Jones Industrial Average increased by 0.89%, and the Nasdaq 100 Index climbed by 1.17%, indicating a sustained rebound in the artificial intelligence trade that boosts market confidence and investor sentiment.
- Crude Oil Price Decline: WTI crude oil prices fell by 2% to a one-week low, which lowered inflation expectations and provided support for stocks and bonds, reflecting a positive outlook for future economic growth.
- Strong China Trade Data: May exports rose by 19.4% year-on-year, exceeding expectations of 15.0%, while imports increased by 27.4%, surpassing the anticipated 26.0%, indicating positive signals for global economic recovery that could further drive market gains.
- Tech Stocks Lead Gains: Chipmakers and AI infrastructure stocks showed strong performance, with Lam Research up over 4%, and Applied Materials and KLA Corp both rising over 3%, suggesting that the recovery in the tech sector is driving overall market growth.
See More
Key Wall Street Rating Changes Overview
- Toll Brothers Upgrade: KBW upgraded Toll Brothers from market perform to market outperform, reflecting resilient luxury demand and improved fundamentals, which is expected to drive growth in the high-end real estate market.
- Park Aerospace Initiation: Citizens initiated coverage on Park Aerospace with a market outperform rating and a $42 price target, citing significant growth opportunities in aerospace materials, particularly in key commercial aviation engine programs.
- Apple Rating Reaffirmed: Morgan Stanley raised its price target on Apple from $330 to $360, noting that WWDC 2026 demonstrated clear progress on Apple's AI roadmap, although monetization will be a long-term endeavor.
- FuelCell Upgrade to Buy: Canaccord upgraded FuelCell from hold to buy, highlighting that the company has deployed nearly one gigawatt of energy blocks globally over the past two decades, showcasing its technology's viability and market potential.
See More
Cardinal Health Continues Growth with Stock Price Surge
- Outstanding Stock Performance: Cardinal Health achieved a remarkable 74% stock price increase in 2025, followed by a 7.9% rise year-to-date in 2026, reflecting sustained investor confidence in its growth strategy, significantly outperforming peers McKesson and Cencora.
- Enhanced Profitability: In its fiscal Q3 2026 earnings report, the company reported a 35% EPS growth and raised its earnings guidance again, underscoring management's confidence in sustained operational momentum despite macro uncertainties and pricing pressures.
- Strong Specialty Pharmaceutical Business: Cardinal Health's Pharmaceutical and Specialty Solutions segment saw an 11% revenue increase to $56.1 billion and an 18% profit rise in Q3, with expectations for specialty sales to exceed $50 billion in fiscal 2026, indicating robust growth potential in the market.
- Rapid Expansion of New Businesses: The company's
See More
US Stocks Close: Nasdaq Hits 5-Week Low Amid Market Rotations
- Market Volatility: The S&P 500 index fell by 0.26% and the Nasdaq 100 dropped by 1.12% on Tuesday, indicating a shift to a downward trend after an early advance, reflecting investor concerns over tech stocks.
- Energy Price Impact: WTI crude oil prices plunged by 3% to a seven-week low, leading to widespread declines in energy producers' stocks, which exacerbated the overall market weakness and highlighted the direct impact of oil price fluctuations on related sectors.
- Real Estate Market Recovery: US existing home sales rose to 4.17 million in April, a five-month high, boosting the stocks of builders and suppliers, indicating that a recovery in the real estate market could provide positive signals for the economy.
- International Trade Data Improvement: China's May exports increased by 19.4% year-on-year, surpassing expectations, showcasing potential for global economic growth, which may positively influence the US market, despite ongoing uncertainties.
See More
US Stock Market Volatility Amid Falling WTI Crude Prices
- Mixed Market Performance: The S&P 500 index fell by 0.28%, while the Dow Jones Industrial Average rose by 0.19%, and the Nasdaq 100 index dropped by 0.80%, indicating a divergence in market sentiment, particularly with weakness in chipmakers and software stocks weighing on the broader market.
- Crude Oil Price Decline: WTI crude oil prices plunged over 3% to a one-week low, primarily due to the ceasefire agreement between Iran and Israel, leading to expectations of further declines in oil prices that could impact the profitability outlook for energy stocks.
- Positive Economic Data: The US trade deficit narrowed to $55.9 billion in April, better than the expected $56.1 billion, while existing home sales in May rose by 3.2% month-over-month to 4.17 million, indicating resilience in the housing market that may provide support for stocks.
- Company Movements: United Natural Foods saw its stock drop over 12% after reporting Q3 net sales below expectations, while Nuvalent's stock surged over 38% following GSK's agreement to acquire the company for $10.6 billion, reflecting varied market reactions to company fundamentals.
See More
Barclays Upgrades West Pharmaceutical to Overweight, Predicts Upside
- Rating Upgrade: Barclays upgraded West Pharmaceutical (WST) from Equal Weight to Overweight, with analysts citing strong fundamentals that could drive near-term upside, reflecting market confidence in the company's future performance.
- Fundamental Improvement: Analyst Luke Sergott noted that previous overestimations of potential headwinds from multi-dose vials and new oral GLP-1 drugs are not expected to pose significant threats in the coming years, suggesting a more favorable outlook.
- Leadership Advantage: The leadership of newly appointed CEO Michel Lagarde and CFO Bob McMahon, who joined last year, is highlighted as a key factor that could facilitate the company's growth and diversification over the next few years.
- Price Target Increase: Barclays raised its price target for WST from $310 to $400, reflecting analysts' optimistic expectations regarding the company's untapped balance sheet capacity and capital deployment flexibility.
See More
US Stocks Rebound as AI Trade Continues to Gain Momentum
- Market Rebound: The S&P 500 Index rose by 0.93%, the Dow Jones Industrial Average increased by 0.89%, and the Nasdaq 100 Index climbed by 1.17%, indicating a sustained rebound in the artificial intelligence trade that boosts market confidence and investor sentiment.
- Crude Oil Price Decline: WTI crude oil prices fell by 2% to a one-week low, which lowered inflation expectations and provided support for stocks and bonds, reflecting a positive outlook for future economic growth.
- Strong China Trade Data: May exports rose by 19.4% year-on-year, exceeding expectations of 15.0%, while imports increased by 27.4%, surpassing the anticipated 26.0%, indicating positive signals for global economic recovery that could further drive market gains.
- Tech Stocks Lead Gains: Chipmakers and AI infrastructure stocks showed strong performance, with Lam Research up over 4%, and Applied Materials and KLA Corp both rising over 3%, suggesting that the recovery in the tech sector is driving overall market growth.
See More
Key Wall Street Rating Changes Overview
- Toll Brothers Upgrade: KBW upgraded Toll Brothers from market perform to market outperform, reflecting resilient luxury demand and improved fundamentals, which is expected to drive growth in the high-end real estate market.
- Park Aerospace Initiation: Citizens initiated coverage on Park Aerospace with a market outperform rating and a $42 price target, citing significant growth opportunities in aerospace materials, particularly in key commercial aviation engine programs.
- Apple Rating Reaffirmed: Morgan Stanley raised its price target on Apple from $330 to $360, noting that WWDC 2026 demonstrated clear progress on Apple's AI roadmap, although monetization will be a long-term endeavor.
- FuelCell Upgrade to Buy: Canaccord upgraded FuelCell from hold to buy, highlighting that the company has deployed nearly one gigawatt of energy blocks globally over the past two decades, showcasing its technology's viability and market potential.
See More
